Seed-Sized Injectable Stimulator Delivers Wireless Peripheral Neuromodulation

A seed-sized device injected through a standard needle can modulate peripheral nerve activity without surgery, batteries, or leads, according to a study published October 10, 2026, in Science Advances. The bioelectronic interface, developed at NYU Abu Dhabi in partnership with Cleveland Clinic Abu Dhabi, delivered programmable electrical stimulation to nerves in vivo — in living organisms, not isolated bench preparations — while drawing all power wirelessly from outside the body.

The paper, first-authored by Research Associate Dr. Mohamed Elsherif and senior-authored by Prof. Khalil Ramadi, Assistant Professor of Bioengineering at NYU Abu Dhabi and NYU Tandon, reports a leadless platform for battery-free wireless peripheral neuromodulation (Science Advances, 12(24), DOI: 10.1126/sciadv.aeg1437). Preclinical testing showed the device could deliver precise stimulation with consistent performance under conditions designed to resemble real-world use.

For neurophysiology readers, the relevance is straightforward: this is a peripheral interface, not a cortical or intracranial system. There is no scalp EEG, ECoG, or MEG component in the published work. The device targets individual peripheral nerves, placing itself in the same clinical territory as conventional surgically implanted stimulators used for chronic pain and movement disorders — but delivered through a needle.

What does the device actually do?

After injection, clinicians position the implant near a target nerve. It then emits carefully controlled electrical signals that alter that nerve's activity. Power and parameter control remain external, so clinicians or patients can adjust stimulation in real time.

Several design features matter for clinical translation:

• Injectable delivery. The device fits through a standard needle, eliminating surgical implantation and its associated recovery time.
• Wireless, battery-free operation. No internal power source, no leads, no replacement surgeries for battery depletion.
• Imaging visibility. Clinicians can locate and monitor the implant using ultrasound and CT — familiar modalities in any neuromodulation practice — to guide placement and verify position afterward.
• Programmable stimulation. Signal parameters can be tailored to the individual patient, giving providers flexibility in managing abnormal nerve activity.

The authors position the technology as an addition to, not a replacement for, existing options such as medication and surgically implanted stimulators.

What did the researchers say?

Prof. Ramadi framed the work as a conceptual shift in neuromodulation delivery. "This work represents a shift in how we think about treating nerve-related conditions," he said. "By creating a device that can be injected rather than surgically implanted, we are making these therapies simpler, safer, and more accessible, while still maintaining precise control over nerve activity."

Dr. Elsherif, the first author, described the platform's intermediate position on the invasiveness spectrum. "This technology has the potential to bridge the gap between non-invasive therapies and traditional implants," he said. "It opens the door to treatments that are both effective and easy to deliver, which could significantly improve patient care."

Dr. Sawsan Abdel-Razig, Chief Academic Officer at Cleveland Clinic Abu Dhabi, emphasized the institutional collaboration behind the study: "By bringing together multidisciplinary expertise, this work highlights how academic partnerships can accelerate the development of safer, less invasive therapies and expand access to advanced treatments for patients."

What has not been shown yet?

The evidence base remains preclinical. Laboratory experiments and animal testing demonstrated reliable nerve activation, but the device has not relieved chronic pain or improved movement disorders in any human patient. No human trials are reported in the paper.

Clinicians should therefore treat this as investigational work, not an available therapy. The device holds no regulatory clearance described in the publication, and the gap between in vivo animal demonstrations and human chronic-pain outcomes is substantial in neuromodulation.

If subsequent research confirms safety and effectiveness in humans, the platform could reduce procedure-related risks, shorten recovery times, and widen access to peripheral nerve stimulation by removing the surgical bottleneck. The study's additional contributors include Salma Mansour, Zhansaya Makhambetova, Fotoon Aldhanhani, Batoul Khlaifat, Mahmoud Elbeh, Vega Pradana Rachim, and Sohmyung Ha of NYU Abu Dhabi, and Hicham Abada, Juan S. Barajas-Gamboa, and Carlos M. Abril Vega of Cleveland Clinic Abu Dhabi. The next milestone to watch will be the first demonstration of therapeutic effect — pain relief or motor improvement — in human subjects.